Improving Response Inhibition in Parkinson’s Disease with Atomoxetine
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson's disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore examined the effect of the selective noradrenaline reuptake inhibitor atomoxetine on response inhibition in a stop-signal paradigm. METHODS: This pharmacological functional magnetic resonance imaging study used a double-blinded randomized crossover design with low-frequency inhibition trials distributed among frequent Go trials. Twenty-one patients received 40 mg atomoxetine or placebo. Control subjects were tested on no-drug. The effects of disease and drug on behavioral performance, regional brain activity, and functional connectivity were analyzed using general linear models. Anatomical connectivity was examined using diffusion-weighted imaging. RESULTS: Patients with Parkinson's disease had longer stop-signal reaction times, less stop-related activation in the right inferior frontal gyrus (RIFG), and weaker functional connectivity between the RIFG and striatum compared with control subjects. Atomoxetine enhanced stop-related RIFG activation in proportion to disease severity. Although there was no overall behavioral benefit from atomoxetine, analyses of individual differences revealed that enhanced response inhibition by atomoxetine was associated with increased RIFG activation and functional frontostriatal connectivity. Improved performance was more likely in patients with higher structural frontostriatal connectivity. CONCLUSIONS: This study suggests that enhanced prefrontal cortical activation and frontostriatal connectivity by atomoxetine may improve response inhibition in Parkinson's disease. These results point the way to new stratified clinical trials of atomoxetine to treat impulsivity in selected patients with Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SMITH, S., & NICHOLS, T. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.061 · Cited by 5,250
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
On the ability to inhibit thought and action: a theory of an act of control
Logan, G. D., & Cowan, W. B. (1984) · Psychological Review · doi:10.1037/0033-295x.91.3.295 · Cited by 2,590
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Rubia, K., Russell, T., Overmeyer, S., Brammer, M. J., Bullmore, E. T., Sharma, T., Simmons, A., Williams, S. C. R., Giampietro, V., Andrew, C. M., et al. (2001) · NeuroImage · doi:10.1006/nimg.2000.0685 · Cited by 999 · cited 1×
“In contrast, a similar dose of atomoxetine had no effect (or even negative impact) on NoGo inhibition in healthy adults (20,21), which supports preclinical evidence of a neuropharmacologic distinction between restraint and cancellation type inhibition (22,23).”
ResultAssociation of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 2×
“Go), was significantly reduced in PD-placebo compared with control subjects (disease effect, peak [56 16 12], t 5 3.”
BackgroundSelf-citationEagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548
Self-citationCools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2003) · Neuropsychologia · doi:10.1016/s0028-3932(03)00117-9 · Cited by 516 · cited 1×
“Corrected pðrespondjsignalÞ 5 Observed pðrespondj signalÞ= 12Go omission rate ð Þ (1)”
Self-citationRobbins, T. W. (2007) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2007.2097 · Cited by 413 · cited 3×
“Noradrenergic systems may therefore support multiple executive processes, including control of motor and nonmotor impulsivity, response inhibition, and cognitive flexibility (21,55), which requires further evaluation for PD.”
BackgroundSelf-citation
Cited by
Cam-CAN, Shafto, M. A., Tyler, L. K., Dixon, M., Taylor, J. R., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., et al. (2014) · BMC Neurology · doi:10.1186/s12883-014-0204-1 · Cited by 707
Self-citationFractionating impulsivity: neuropsychiatric implications
Dalley, J. W., & Robbins, T. W. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.8 · Cited by 607
Self-citationLocus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
Self-citationRae, C. L., Hughes, L. E., Anderson, M. C., & Rowe, J. B. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3093-13.2015 · Cited by 274
Self-citationFox, H., Sofuoglu, M., & Sinha, R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114562464 · Cited by 30
“Both medications have been shown to improve inhibitory-related processes in non-human primates as well as humans with ADHD, tic disorders and neurodegenerative disorders (Arnsten and Li, 2005; Gau and Shang, 2010; Hunt et al., 1995; Jakala et al., 1999a; Scahill et al., 2001; Shang and Gau, 2012; Swartz et al., 2008;…”
Atomoxetine and citalopram alter brain network organization in Parkinson’s disease
Borchert, R. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, S. P., Vatansever, D., Vázquez Rodríguez, P., Ye, Z., Nombela, C., Hughes, L. E., et al. (2019) · Brain Communications · doi:10.1093/braincomms/fcz013 · Cited by 14
Self-citationTrempler, I., Bürkner, P.-C., El-Sourani, N., Binder, E., Reker, P., Fink, G. R., & Schubotz, R. I. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116674 · Cited by 6
Linkovski, O., Naftalovich, H., David, M., Seror, Y., & Kalanthroff, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124075 · Cited by 3
“has also been shown to improve inhibitory control [27,28].”
Background
Metadata
- Authors
- Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 77
- Issue
- 8
- Pages
- 740-748
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2058481315
- Cited by
- 105
- References
- 26
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.